News
  • Facebook
  • LINE
  • Twitter
  • LinkedIn

FDA approves GSH-BGM902 Blood Glucose Monitoring System

2017/9/28
FDA approves GSH-BGM902 Blood Glucose Monitoring System

Show Details

The U.S. Food and Drug Administration this mouth approved the GSH-BGM902 Blood Glucose Monitoring System, the glucose monitoring system that can be used by adult patients to record diabetes treatment result with Bluetooth technology .

The system reduces the need for paper work by using Bluetooth technology. Users can determine glucose levels by checking the WowGoHealth APP if glucose levels are too high (hyperglycemia) or too low (hypoglycemia), and how glucose levels are changing.

The WowGoHealth Blood Glucose Monitoring System (Model GSH-BGM902) consists of the WowGoHealth Blood Glucose Monitor and the WowGoHealth Blood Glucose Test Strip. The WowGoHealth Blood Glucose Monitoring System (Model GSH-BGM902) is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips or forearm. The WowGoHealth Blood Glucose Monitoring System (Model GSH-BGM902) is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program.

※ The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Other News

Previous Page